Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.110
-0.020 (-0.48%)
At close: Dec 30, 2025, 4:00 PM EST
4.120
+0.010 (0.23%)
After-hours: Dec 30, 2025, 7:59 PM EST
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $5.18M in the quarter ending September 30, 2025, a decrease of -80.16%. This brings the company's revenue in the last twelve months to $43.69M, down -32.98% year-over-year. In the year 2024, Recursion Pharmaceuticals had annual revenue of $58.84M with 32.00% growth.
Revenue (ttm)
$43.69M
Revenue Growth
-32.98%
P/S Ratio
37.73
Revenue / Employee
$54,611
Employees
800
Market Cap
2.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RXRX News
- 4 days ago - 3 Small AI Plays to Buy for 2026 - Benzinga
- 12 days ago - Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 - Seeking Alpha
- 12 days ago - What's Happening With RXRX Stock? - Forbes
- 22 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript - Seeking Alpha
- 22 days ago - Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial - Reuters
- 22 days ago - Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks - GlobeNewsWire
- 25 days ago - Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
- 4 weeks ago - Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 - GlobeNewsWire